Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively.
D000293:Adolescent; D000707:Anaphylaxis / Q000517:prevention & control; D002648:Child; D002675:Child, Preschool; D006699:Home Care Services; D018718:Home Infusion Therapy / Q000009:adverse effects* / Q000379:methods*; D006701:Home Nursing; D006801:Humans; D007066:Iduronate Sulfatase / Q000008:administration & dosage*; D016532:Mucopolysaccharidosis II / Q000188:drug therapy*; D009087:Mucopolysaccharidosis VI / Q000188:drug therapy*; D020051:N-Acetylgalactosamine-4-Sulfatase / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome
D011994:Recombinant Proteins; D020051:N-Acetylgalactosamine-4-Sulfatase; C508864:galsulfase; D007066:Iduronate Sulfatase; C517982:idursulfase